|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8614178||NOVALIQ GMBH||Pharmaceutical composition for treatment of dry eye syndrome|| |
(7 years from now)
|US10813976||NOVALIQ GMBH||Ophthalmic compositions comprising ciclosporin|| |
(14 years from now)
|US11154513||NOVALIQ GMBH||Semifluorinated compounds|| |
(15 years from now)
|US11413323||NOVALIQ GMBH||Ophthalmic composition for treatment of dry eye disease|| |
(16 years from now)
Vevye is owned by Novaliq Gmbh.
Vevye contains Cyclosporine.
Vevye has a total of 4 drug patents out of which 0 drug patents have expired.
Vevye was authorised for market use on 30 May, 2023.
Vevye is available in solution;ophthalmic dosage forms.
Vevye can be used as treatment of dry eye disease (ded), treatment of the signs and symptoms of dry eye disease (ded).
The generics of Vevye are possible to be released after 11 October, 2039.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Product (NP)||May 30, 2026|
Market Authorisation Date: 30 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of dry eye disease (ded)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic